Despite acknowledging the medical benefits of an innovative drug prescribed to treat a rare illness, public health authorities were slow to authorise its reimbursement.
Prescribed alongside a course of treatment, the drug in question delivered significant provable results in terms of improved survival rates but was seen as being too expensive, given the profile of the people most impacted. The association was keen to identify new mechanisms to create awareness of a rare pathology with very limited public recognition.
